Lmcg Investments LLC Sells 2,014 Shares of AstraZeneca PLC (NASDAQ:AZN)

Lmcg Investments LLC lessened its position in AstraZeneca PLC (NASDAQ:AZN) by 4.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 40,359 shares of the company’s stock after selling 2,014 shares during the quarter. Lmcg Investments LLC’s holdings in AstraZeneca were worth $3,144,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in AZN. Diversified Trust Co lifted its holdings in shares of AstraZeneca by 5.8% in the 1st quarter. Diversified Trust Co now owns 4,343 shares of the company’s stock worth $294,000 after acquiring an additional 238 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in shares of AstraZeneca by 172.9% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 10,496 shares of the company’s stock worth $711,000 after acquiring an additional 6,650 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in shares of AstraZeneca by 20.4% in the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 78,873 shares of the company’s stock worth $5,344,000 after acquiring an additional 13,373 shares during the last quarter. Norden Group LLC bought a new stake in shares of AstraZeneca in the 1st quarter worth about $3,055,000. Finally, Kovack Advisors Inc. bought a new stake in shares of AstraZeneca in the 1st quarter worth about $202,000. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Up 0.4 %

NASDAQ AZN traded up $0.27 during trading on Friday, reaching $71.42. 3,474,414 shares of the company’s stock traded hands, compared to its average volume of 3,430,014. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.89 and a quick ratio of 0.69. The firm has a market cap of $221.44 billion, a price-to-earnings ratio of 34.50, a price-to-earnings-growth ratio of 1.32 and a beta of 0.47. The company’s 50 day simple moving average is $79.17 and its two-hundred day simple moving average is $78.60. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $87.68.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. TD Cowen lifted their price objective on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a report on Monday, August 12th. Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of AstraZeneca from a “hold” rating to a “sell” rating in a report on Friday, September 13th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.